The cytokines released from Th2 and Th2-like cells are likely to be central to the pathophysiology of asthma and allergy, contributing to aberrant IgE production, eosinophilia and, perhaps, mucosal susceptibility to viral infection. IL-4 has emerged as a central target, not only for B cell IgE production, but also in the commitment of both CD4+ and CD8+ T cells to cells with Th2 effector function capable of secreting IL-5 resulting in eosinophilic inflammation. In view of the central role of this cytokine and the evidence that glucocorticoids are unable to modify many IL-4 dependent effects, Th2 inhibitors may prove to be novel therapies for the treatment of bronchial asthma.

Keywords: Cytokines, Inflammation, Lung, Th2 cells.

Introduction

There is now increasing evidence to suggest that pro-inflammatory cytokines derived from various subsets of T cells play a major role in the induction of allergic inflammation of the lungs. Additionally, cytokines derived from other cell types such as mast cells and eosinophils may also be of importance in the maintenance/persistence of this disease. This review discusses the interactive cytokine networks that exist in the lungs, which are believed to play an important role in the aetiology of bronchial asthma.

Pathology of asthma

Bronchial hyperresponsiveness (BHR) to both specific and nonspecific stimuli is a characteristic feature of bronchial asthma. While the mechanisms underlying this exaggerated responsiveness are still unclear, there is a considerable body of evidence to suggest that mucosal inflammation of the airways is of central importance. Perhaps the most common pathological finding is an increased number of eosinophils and mast cells in the lung mucosa. It is currently believed that damage to the epithelium is mediated by the secretion of eosinophil-derived highly toxic cationic proteins such as major basic protein (MBP). In addition, ultrastructural abnormalities in the architecture of the lungs of asthmatic individuals have been reported, characterized by subepithelial deposition of collagen types III and V and fibronectin, the amount of which is correlated with the number of myofibroblasts. More recently, attention has been focused on the role of lymphocytes in the pathophysiology of this disease. In severe acute asthma, an increase in the number of T cells expressing the activation markers HLA-DR, CD25 and VLA-1 has been reported. The realization that CD4+ T cells can be committed to a distinct phenotype that can induce B cells to switch to IgE production and recruit eosinophils to the lungs, mediated via the secretion of cytokines, has led to the hypothesis that lymphocytes play a major role in orchestrating the inflammatory response in the lungs of asthmatic individuals.

CD4+ T cell subsets—the Th2 hypothesis

Mature T cells in the periphery can be divided into either CD4+ and CD8+ populations. This subdivision is associated with fundamental differences in their function, in that CD4+ T cells are activated by soluble foreign proteins such as allergens, presented by MHC class II molecules on the cell surface of antigen presenting cells (B cells, macrophages and dendritic cells). In contrast, CD8+ T cells are, in general, activated by intracellular pathogens such as viruses, are MHC class I restricted and are cytotoxic. Murine CD4+ T cells can be further subdivided into two distinct subsets, termed T helper 1 (Th1) and T helper 2 (Th2), on the basis of their restricted cytokine profile and ability to mediate different immune functions. Activated antigen-naive resting CD4+ T cell cells secrete mainly IL-2. However, these cells can be primed under the influence of different cytokines (and perhaps dif-
ferent co-stimulatory signals) to either a Th1 or Th2 subset. Th1 cells produce TNF-β and IFN-γ and are involved in delayed hypersensitivity responses. Th2 cells produce IL-4, IL-5 and IL-10 and provide help to B cells and as such, are believed to play a central role in the aetiology of allergic disease.3

**Th2 cells in asthma**

While the concept of Th2 subtype of CD4+ T cells was originally defined in murine cell clones, there is now evidence to suggest that a similar cytokine profile exists in individuals with allergic disease. Studies of T cell clones obtained from the blood of patients sensitive to house dust mite allergen demonstrated that the majority of these clones produced IL-4 and IL-5 and low levels of IFN-γ and IL-2 after antigen stimulation.12 Likewise, lymphocytes obtained by bronchoalveolar lavage after allergen provocation of allergic individuals have increased expression of mRNA for IL-3, IL-4 and IL-5. IL-5 mRNA has also been identified by in situ hybridization of tissues obtained by bronchiolar biopsies of asthmatic subjects and localized to beneath the epithelial basement membrane.67 However, it is important to realize that the Th1/Th2 concept is based on extremely polarized panels of cytokines which can be generated in vitro by murine CD4+ T cells and it is likely that more subtle intermediate phenotypes exist in human disease.

**Antigen specific activation of CD4+ T cells**

Activation of CD4+ T cells require interaction between CD3 associated TCR α/β complex and specific antigen presented as peptides by class II bearing cells. However, for complete cellular activation, a second signal is also required. Moreover, antigen stimulation through the TCR in the absence of co-stimulation leads to a state of unresponsiveness or clonal anergy. The most extensively studied co-stimulatory molecule is CD28, which is constitutively expressed on the surface of naïve CD4+ T cells, the engagement of which is required for IL-2 production and T cell proliferation.8 The importance of this pathway is illustrated in mice lacking the gene for CD28 which exhibit impaired lymphokine secretion.9 The first ligand for CD28, initially termed B7 (now classified as CD80), was identified on the surface of the B cell and subsequently shown to provide co-stimulatory signals to antigen activated T cells.1011 However, the demonstration that B7-knockout mice had virtually no immune defects led to the speculation that additional CD28 ligands existed.12 This indeed proved to be the case and a second co-stimulatory molecule termed B7-2 (CD86) has more recently been identified.13 B7-2 is expressed at extremely low levels on resting B cells, but is rapidly upregulated after cross linking of the B cell antigen receptor or following stimulation with LPS.14 On human B cells, B7-2 expression peaks within 24 h of activation, whereas B7-1 expression peaks several days later.15 In addition, a second CD4+ T cell co-receptor, homologous to CD28 has been identified, termed CTLA-4 and demonstrated to be a second ligand for B7-1 and B7-2.16 The different functional importance of CD28 and CTLA-4 is still unclear. However, in contrast to CD28, CTLA-4 expression is increased only after activation,17 and as such may function to downregulate the T cell response.18

While the importance of these co-stimulatory signals for the production of IL-2 is well established, the role of these co-stimulatory molecules in the production of Th2 pattern of cytokines is less clear. However, it has recently been reported that stimulation through CD28 induces a Th2 response in vitro independent of IL-4 production.19 CD28 mediated stimulation of cloned human Th2 clones has also been reported to induce responsiveness to IL-4 via the autocrine production of IL-1α.19 In vivo, administration of CTLA-4 Ig can inhibit IL-4 gene expression and IgE production following infection with *Heligmosomoides polygyrus.*20 Further evidence that co-stimulation modifies the outcome of an immune response is provided by the observation that treatment with CTLA-4 Ig prevents IL-4 production following immunization with goat-anti-IgD.21 In contrast, mice transgenic for soluble murine CTLA-4 Ig exhibit normal T cell priming and cytokine production after immunization with a T cell dependent antigen.22 The reasons for these discrepancies are unclear, but may be related to insufficient levels of CTLA-4 Ig in vivo to block interactions between APC and T cells.

**Cytokines and allergic inflammation**

*Regulation of IgE production:* The principal feature that distinguishes atopic from non-atopic individuals is their ability to develop IgE antibodies to foreign proteins. During a CD4-MHC class II dependent cognate interaction of T and B cells, contact-mediated costimulatory signals provided by CD4+ T cells such as CD40L and membrane TNF-α, initiate B cell activation. During this process, IL-4 has been demonstrated
in murine\textsuperscript{23,24} and human\textsuperscript{25,26} systems to instruct B cell to switch to IgE production. Investigation of T cell cytokine production indicates that enhanced \textit{in vitro} IL-4 production is correlated with enhanced \textit{in vivo} IgE production. Whereas T cell membrane-dependent activation signals are regarded as general competence signals to initiate B cell activation and induce cytokine responsiveness, cytokines such as IL-4 provide a progressive signal inducing proliferation and switching of B cells to IgE. Inhibition of IL-4 \textit{in vivo}, either by administration of anti-IL-4 antibodies\textsuperscript{24} or by deletion of the IL-4 gene,\textsuperscript{27} has revealed the essential requirement of IL-4 for the switch to IgE production. However, a recent study has demonstrated that IL-4 independent IgE production can occur, although at a greatly reduced level in IL-4 gene targeted mice.\textsuperscript{28} However, to what degree such production might be mediated by already switched B cells remains to be determined. The situation, however, is more complex in humans as IL-13, the message of which has been found in murine and human CD4\textsuperscript{+} cell clones of Th0 and Th2 phenotype, as well as CD8 T cell clones,\textsuperscript{29} can also induce immunoglobulin isotype switching to IgE production.\textsuperscript{30} The precise importance of IL-4 vs. IL-13 as the principal cytokine involved in B cell isotope switch in allergic disease is at present unclear. However, recent studies have demonstrated that naive CD4\textsuperscript{+} T cells (CD45RO\textsuperscript{--}) primed through the TCR develop into effector cells that secrete IL-5 and IFN-\gamma and help B cell IgE production via IL-13 and not IL-4.\textsuperscript{31} In contrast, activation of CD4\textsuperscript{+} memory cells (CD45RO\textsuperscript{+}) also produce IL-4 and IL-5 and help B cell IgE through a combination of IL-13 and IL-4.\textsuperscript{31}

IL-4 also plays a central role in the induction of the Th2 phenotype as shown by \textit{in vitro} and \textit{in vivo} experiments using IL-4 gene detected mice. The importance of IL-4 in the cytokine networks in the lung are discussed in more detail in the next section.

\textit{Development of eosinophilic inflammation:} Over 20 years ago, the development of eosinophilia in nematode infected rodents was demonstrated to be lymphocyte dependent.\textsuperscript{32} Subsequently, it was shown that the soluble factor from T cells was identical to B cell growth factor 2 (BCF II). This factor has been extensively studied and characterized and is now termed interleukin-5 (IL-5). IL-5 has been shown to promote the growth and differentiation of eosinophils in culture and, in contrast to IL-3 and GM-CSF, acts as a terminal eosinophil differentiation factor. \textit{In vivo}, administration of exogenous IL-5 induces eosinophil recruitment\textsuperscript{33} and transgenic mice overexpressing the IL-5 gene develop peripheral blood, bone marrow and tissue eosinophilia.\textsuperscript{34} Furthermore, administration of anti-IL-5 has been demonstrated to inhibit eosinophilia induced by nematodes\textsuperscript{35} or antigen in sensitized animals.\textsuperscript{36} The precise source of IL-5 required for the induction of eosinophil infiltration is at present unclear, although it is likely that it is produced from CD4\textsuperscript{+} T cells. IL-5 (in addition to IL-3 and GM-CSF) is also required for the survival of eosinophils \textit{in vitro}.\textsuperscript{37,38} However, in contrast to the requirement for CD4\textsuperscript{+} T cell derived IL-5 for the recruitment of eosinophils to the lung,\textsuperscript{39} the source of IL-5 required for the survival of eosinophils in the lungs is from a non-CD4\textsuperscript{+} T cell source, possibly involving autocrine production from the eosinophil itself.\textsuperscript{40} IL-5 however, may not be the only factor involved in recruiting eosinophils to the mucosa and/or promoting their survival and activation, as the observation of a complete inhibition of eosinophil infiltration into the airways after antigen challenge in mice lacking the IL-5 gene (M. Kopf, personal communication) may also reflect the requirement for maturation of eosinophils in the bone marrow. In this regard, other cytokines including the chemokines RANTES and the recently identified eotaxin, may also be important in recruiting eosinophils to the lung.

RANTES, along with IL-8, MCP-1, MCAF and eotaxin belong to the superfamily of structurally related low molecular weight cytokines which contain four cysteines at identical relative positions with a conserved Cys-Cys-(C-C) motif. RANTES was originally identified as an apparently T cell-specific inducible gene that was expressed by cultured T cell lines.\textsuperscript{41} More recently, RANTES has been shown to be produced from activated platelets.\textsuperscript{42} RANTES is eosinophil chemotactic for both eosinophils and for 'memory' CD4\textsuperscript{+} T cells \textit{in vitro} and as such may contribute to the eosinophil recruitment in allergic disease.\textsuperscript{43}

Eotaxin, was originally identified as a factor produced in the BAL of antigen-challenged guinea-pigs, which, upon subsequent injection, induced a selective accumulation of eosinophils in the skin\textsuperscript{44} and lungs.\textsuperscript{45} Eotaxin has a 53% homology with MCP-1, 31% with MIP 1\alpha and 26% with RANTES. mRNA for eotaxin was shown to be up-regulated 3h after allergen provocation.\textsuperscript{46} The role of eotaxin and other C-C chemokines in the airways of asthmatic individuals remains to be determined.

CD8\textsuperscript{+} Th2 like cells—a mechanism for viral used exacerbations of asthma: CD8\textsuperscript{+} T cells typically produce a Th1 like cytokine panel (IFN-
γ, IL-2) after *in vitro* stimulation. CD8+ T cells mediate lysis of viral infected cells and inhibition of viral replication through the production of IFN-γ. Moreover, it has been suggested that CD8+ T cells down-regulate the CD4+ T cell driven response dependent on the production of IFN-γ. However, recent observations from Erard and colleagues have shown that in the presence of IL-4, activated CD8+ cells can switch their function to produce Th2 cytokines. Additionally, these cells produce less IFN-γ and lose their cytotoxic potential. This suggests that in allergic individuals, CD8+ T cell function may be re-directed if activated by a specific antigen in the presence of IL-4. In this context, it has recently been demonstrated that MHC class I restricted viral antigen-specific activation of CD8+ T cells in the presence of IL-4, leads to a phenotype that produces IL-5 and reduced amounts of IFN-γ. Moreover, *in vivo*, the induction of an IL-4-dependent Th2 phenotype can switch viral-specific CD8+ T cells to produce IL-5 and induce eosinophil recruitment into the lungs. These observations suggest that IL-4 is important not only in regulation of CD4+ T cell commitment, but has dramatic effects on CD8+ T cell function. Thus, this IL-4 mediated switch of CD8+ T cells to a Th2 like phenotype, may not only exacerbate asthma severity by secreting IL-5, but the reduction in IFN-γ secretion may impair the normal host response, leading to delayed viral clearance from the lung.

**IL-4 and steroid resistant asthma:** Glucocorticosteroids are the single most effective class of drug able to control symptoms and suppress overt airway inflammation in asthma, and are increasingly widely used as first line therapy. It has recently been reported that treatment of allergic individuals with systemic prednisolone inhibits the expression of mRNA for IL-4 and IL-5 mRNA, whilst increasing mRNA for IFN-γ, suggesting that one of the therapeutic effects of this drug is to inhibit Th2 cell activation. Steroids may also be effective by inducing apoptosis of eosinophils in the inflamed mucosa, by suppressing IL-3, GM-CSF and IL-5 synthesis.

However, steroids are unable to suppress IL-4 induced up-regulation of the endothelial adhesion ligand for eosinophils, and VCAM-1 and can enhance IL-4-driven IgE production in normal human lymphocytes. Furthermore, in a Th2-like T cell line, IL-4 selectively inhibits dexamethasone-induced apoptosis. In this context, it has recently been demonstrated that *in vitro* steroids are unable to inhibit IL-4 secretion from murine Th2 cells. Together, these observations suggest that steroids may not be able to inhibit some of the effects and the production of IL-4, and may therefore be intrinsically unable to suppress the central underlying immunological processes that drive eosinophilic inflammation in the mucosa.

More recently, it has been shown that prednisolone therapy fails to down-regulate mRNA for IL-4 and IL-5 in steroid resistant asthmatics. While the precise mechanisms by which steroid resistance occurs is unclear, it has recently been demonstrated that IL-4 can down-regulate the glucocorticoid receptor affinity *in vitro*. These observations suggest that inhibition of IL-4 may, in addition to providing an alternative therapy to steroids, prove to be a useful adjunct therapy in the treatment of asthma by possibly restoring normal steroid receptor function.

**Cytokine regulation of Th1 and Th2 cell commitment**

Activated antigen-naive resting CD4+ T cell cells from non-allergic donors secrete mainly IL-2, with a very low production of IL-4 and IFN-γ. These cells must be 'primed' or 'committed' to either a Th1 (IFN-γ producing) or Th2 (IL-4 producing) phenotype. It is now well established *in vitro* that IL-4 is essential for the commitment of naive CD4+ T cells to the Th2 phenotype after either stimulation through the CD3 complex or by a specific antigen. Likewise, studies performed in mice lacking the IL-4 gene have demonstrated the essential role of this cytokine in the development of Th2 immune response, as *ex vivo* stimulation of CD4+ T cells from these mice causes the secretion of greatly reduced amounts of IL-5 and IL-10, and fail to mount an IgE response. Likewise, these mice have a marked attenuation of IL-5 dependent lung eosinophil recruitment following allergen provocation. The initial source of IL-4 required for Th2 commitment is at present uncertain. As discussed below, mast cells and basophils can produce IL-4 following cross-linking of IgE bound to the FcεR1. However, it is unlikely that mast cells would function as the primary source of IL-4 as in murine systems IgE production is strictly IL-4 dependent. Moreover, adoptive transfer of CD4+ T cells alone from normal mice to IL-4 gene deleted mice results in the development of an IgE response following immunization, suggesting that for the induction of the B cell isotype switch to IgE, IL-4 is derived solely from CD4+ T cells. More recently, a small subpopulation of T cells derived from the spleen and bearing the markers
CD4+/NKI.1+ have been shown to rapidly produce IL-4 mRNA upon activation, independent of IL-4 itself. These observations suggest that possibly these cells can provide the first source of IL-4 at the outset of the immune response which subsequently primes naive CD4+ T cells to the Th2 phenotype. IL-10 is a major cytokine produced by several different cell types. Mouse IL-10 is secreted from Th2, but not Th1 cells. In addition, mouse CD5+ B cells produce IL-10 and it has been suggested that autocrine production of IL-10 by these cells acts as a growth factor. Murine macrophages are also a source of IL-10. In contrast, the production of IL-10 by human cells is not restricted to Th2 cells, and approximately one-third of CD8+ T cell clones, as well as Th0 and Th1 cells, produce IL-10 upon restimulation. In comparison to other cytokines, IL-10 is synthesized at a late stage after activation, with maximal expression of mRNA 24 h and protein production 48 h later. IL-10 inhibits production of IFN-γ and the proliferation of Th1, but not Th2 cells. Moreover, inhibition was observed only in the presence of macrophages and not B cells, suggesting an indirect mode of action via the antigen-presenting cell itself. This inhibition appears to be unrelated to antigen processing, as IL-10 also inhibited cytokine production from Th1 cells induced by superantigens. IL-10 is a potent suppressor of macrophage activation and inhibits the production of IL-1α, IL-1β, IL-6, IL-8, TNF-α and GM-CSF from monocytes at both the protein and transcriptional level. IL-10, like IL-4, up-regulates class II MHC expression on small resting B cells and maintains their viability in vitro, although in contrast to IL-4, IL-10 failed to increase expression of CD23. Thus, IL-10 appears to down-regulate the immune response by inhibiting the production of pro-inflammatory cytokines. In this context, it has recently been demonstrated that IL-10 will inhibit the accumulation of eosinophils in the lung after antigen challenge, associated with a suppression of TNF-α in the bronchoalveolar lavage fluid.

IFN-γ has been shown to inhibit proliferation of Th2 cells and to inhibit IL-4 induced Th2 phenotype commitment. Furthermore, IFN-γ has been shown to prime cells for further IFN-γ production. In vitro, IFN-γ has been shown to inhibit the recruitment of eosinophils to the lungs of sensitized mice. Moreover, anti-IFN-γ potentiates the antigen-induced eosinophil accumulation, suggesting that endogenous IFN-γ secreted following aerosol antigen provocation acts to inhibit mucosal Th2 immune responses. It has therefore been proposed that the balance between IL-4 and IFN-γ production will determine whether a Th1 or a Th2 phenotype is produced. This cross regulation has been elegantly demonstrated in models of parasite infection where neutralizing antibodies against IL-4 or IFN-γ have been used to resolve or promote infection by biasing the immune response in favour of Th1 or Th2 immunity.

IL-12 is also believed to play a central role in the regulation of the immune response. IL-12, like TNF-α, IL-1 and IL-6, is secreted principally from macrophages in response to bacterial or viral pathogens. IL-12 has been reported to facilitate the development of the Th1 phenotype, efficiently prime cells for IFN-γ production and inhibit the commitment of IL-4 producing cells. Similarly in vivo, IL-12 shifts the immune response from an IL-4 producing to an IFN-γ producing phenotype and provides protection against Leishmania major infection where Th2 responses are lethal. More recently, it has been demonstrated that IL-12 will inhibit IL-4, IL-5, IL-6 and IL-13 mRNA and potentiate expression of mRNA for IFN-γ, IL-2 and IL-10 after infection with Schistosoma mansoni. Studies using neutralizing antibodies to IFN-γ demonstrated that the effects of IL-12 on expression of IL-2, IL-4 and IL-13 were mediated through IFN-γ production. However, the suppressive effects of IL-12 on mRNA for IL-5 and IL-6 were relatively refractory to IFN-γ raising the possibility that IL-12 may be a more important regulator of IL-5 production than IFN-γ. In human T cells, IL-12 can switch the in vitro recall response of allergen-specific T cells from atopic donors, from a Th2 to a Th1 phenotype, suggesting that IL-12 can not only commit cells to a Th1 phenotype, but also has the potential to reverse established immune response.

IFN-α has a wide range of immunomodulatory activity and has been shown to suppress IgE production both in vivo and in vitro. However, a direct effect on B cells is unlikely as IFN-α fails to inhibit B cell switch in vitro unless IFN-γ is present. The hypothesis that IFN-α mediates its suppressive effect via IFN-γ production is supported by the finding that IFN-α induced inhibition of anti-IgD induced IgE and IgG1 production is associated with an increase in splenic mRNA for IFN-γ. This hypothesis has recently been supported using human CD4+ T cells, showing IFN-α increases the frequency of IFN-γ producing CD4+ T cells and antagonizes the suppressive effects of IL-4 on IFN-γ production. As a consequence, both IL-12 IFN-γ and IFN-α may favour the induction and maintenance of Th1 cells and counteract Th2 driven allergic reactions.
Cytokines from a non-CD4+ T cell source

Mast cells and basophils: Mast cell metaplasia in the bronchial mucosa is a pathological feature of chronic asthma. Mast cells have been shown to be a rich source of cytokines and as such may not only contribute to the acute responses following antigen challenge, but may also play an important role in the persistence of airway inflammation. Murine non-B/non-T cells (either mast cells or basophils) have been reported to secrete IL-4 and IL-6,79 as well as TNF-α and GM-CSF upon cross linking of the Fce receptor.79 Likewise, human mast cells also secrete IL-4 upon IgE specific activation.80 More recently, it has been shown that murine mast cells can also synthesize and secrete IL-13 upon IgE dependent activation and induce IgE transcripts.80 Additionally, mast cells produce IL-3, which together with IL-5, facilitate expansion of the eosinophil lineage and enhance eosinophil survival. IL-3 can also prime mast cells for cytokine production (Table 1). Metachromatic cells may therefore have an important role as rapid sources of cytokines triggered by IgE-dependent cell activation. Indeed, a positive feedback loop may operate involving IgE, mast cells and Th2 cytokines derived from CD4+ T cells. Thus, antigen exposure would lead to the production of IL-4 from CD4+ T cells which would then express CD40L upon activation and facilitate the production of IgE, which in turn would 'arm' mast cells with the specific antibody. Activation of mast cells and basophils upon re-exposure to the antigen would then lead to IL-4 production and amplification of the Th2 response (Fig. 2).

Eosinophils: While there is a considerable body of evidence to suggest that eosinophils are final effector cells in the pathogenesis of allergic disease and bronchial asthma, mediated largely through the secretion of cationic proteins,81,82 these cells also have the capacity to synthesize and release a wide array of cytokines. Additionally, eosinophils express various surface markers which suggest that they also may be immunologically competent cells. In this respect, it has recently been demonstrated that eosinophils express CD40L upon activation, suggesting that these cells may be able to provide efficient help to B cells to produce antibodies.83 Human eosinophils can store IL-5 in the granular matrix which is secreted by either IgA, IgG or IgE dependent mechanisms.84 Likewise, eosinophils can also produce IL-3 and GM-CSF and as such, eosinophil activation may provide, in an autocrine fashion, its own survival factors. Stimulation of human eosinophils with calcium ionophore also leads to the production of IL-8.85 However, while IL-8 generation by monocytes or neutrophils can be induced by IL-1β and TNF-α, these cytokines failed to induce IL-8 secretion from eosinophils. Eosinophils can also secrete TGF-α86 and TGF-β187 and as such may account for the eosinophil-derived stimulatory capacity for fibroblast proliferation.88 This is particularly important in bronchial asthma, where changes in the architecture of the lung may contribute to the irreversibility of this disease. Likewise, human eosinophils synthesize and secrete IL-689 which is able to facilitate IL-4 dependent IgE production, and synergizes with IL-3 and GM-CSF for the maturation of multipotential granulocyte progenitors. Interestingly, IL-6 can also promote the secretions of IgA in mucosal tissue, which may subsequently 'arm' eosinophils to secrete their granular contents following activation.

Th2 inhibitors—novel asthmatic drugs?

Important theoretical questions surround the rational and therapeutic value of Th2 inhibitors as they arise. A central question relates to the role of IL-4 in the longevity and maintenance of Th2 immune responses. While inhibition of IL-4 would prevent the switch B cells to IgE production, it would also inhibit the differentiation of naïve T cells to the Th2 phenotype. However, therapeutically this would be an unachievable goal. As allergic individuals retain their sensitivity to allergens over many decades, it might be supposed that IgE-switched B cells and IL-4 committed Th2 cells retain their phenotypes for prolonged periods. If this is the case, continuous exposure to environmental antigens would be expected to reactivate these immune mechanisms in an IL-4 independent manner. If allergic

| Cytokine | CD4 Th1 | CD4 Th2 | CD8 "TH2 like" | Meta-chromatichelial cells | Eosinophils |
|----------|--------|--------|----------------|--------------------------|------------|
| IFN-γ    | +++    | -      | +++            | +                        | -          |
| TNF      | +++    | -      | +              | nd                       | ++         |
| IL-2     | +++    | -      | ++             | +                        | -          |
| IL-3     | ++     | ++     | +              | nd                       | ++         |
| GM-CSF   | ++     | +++    | +              | nd                       | ++         |
| IL-4     | -      | +++    | +              | +++                      | ++         |
| IL-5     | -      | +++    | -              | +++                      | ++         |
| IL-10    | -      | +++    | -              | +++                      | -          |
| IL-13    | -      | +++    | +              | nd                       | ++         |

The panel of cytokines produced by T cells, metachromatic cells and eosinophils (cytokine production: +++, high; + intermediate; ± detectable; − not detectable; nd not determined).
Th2 cells and cytokines in allergic inflammation

CD40
IL-4/IL-13
eosinohil
Ik-4
TCR
Th2
IL-5
APC

FIG. 1. Hypothetical positive feedback loop for the interaction between mast cells, lymphocytes and eosinophils. Antigen activated Th2 CD4+ T cells, provided with appropriate co-stimulatory signals, secrete IL-4 and express CD40L, and as a consequence instruct B cells to produce IgE. Likewise, Th2 cells produce IL-5 to recruit eosinophils into the lung. Interestingly, activated eosinophils may also express CD40L to help B cell IgE production. IgE can then bind to the FcεRI on mast cells, which, when activated, provide a further source of IL-4 to maintain and amplify the immune response.

immune ‘memory’ (persisting responsiveness to recall antigens) is IL-4 independent, inhibitors of Th2 cytokine production rather than commitment will prove to be of greater therapeutic value. However, in some murine systems of ongoing IgE synthesis, there is evidence that IL-4 is required for the maintenance of the Th2 phenotype. However, the situation may be more complex in humans, where IL-13 dependent ongoing IgE synthesis may be more important. However, inhibition of IL-4 may offer advantages in steroid resistant asthma by preventing/reversing impaired steroid receptor function and in viral mediated exacerbations of asthma, where IL-4 may be of central importance in switching cytotoxic CD8+ T cells to a Th2 like phenotype. Likewise, selective inhibition of IL-5 offers the possibility of selectively suppressing eosinophil infiltration into the airways. However, whether other eosinophil factors such as eotaxin can replace IL-5 in the lung of allergic individuals remains to be determined. Finally, one important point to determine is whether agents that suppress the production of Th2 cytokines from T cells are also effective in suppressing the secretion of cytokines from, for example, mast cells and eosinophils, which may be important sources of cytokines in established chronic asthma.

FIG. 2. Interactive cytokine network regulating the commitment of CD4+ cells to a Th1 or Th2 phenotype.
Conclusions

The cytokines released from Th2 and Th2-like cells are likely to be central to the pathophysiology of asthma and allergy contributing to aberrant IgE production, eosinophilia and, perhaps, mucosal susceptibility to viral infection. IL-4 has emerged as a central target, not only for B cell IgE production, but also in the commitment of both CD4+ and CD8+ T cells to cells with Th2 effector function capable of secreting IL-5 resulting in eosinophilic inflammation. In view of the central role of this cytokine and the evidence that glucocorticoids are unable to modify many IL-4 dependent effects, Th2 inhibitors may prove to be novel therapies for the treatment of bronchial asthma.

References

1. Djukanovic R, Roche WR, Wilson PW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 435-447.
2. Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988; ii 1120-1122.
3. Moreman T, Coffman RL. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173.
4. Linsley PS, Snoddy M, Box JD, Jensen HM, Kapcsocjobp ML. Comparison of diversity and function of house dust mite-specific lymphocyte clones from atopic and non-atopic donors. Eur J Immunol 1990; 20: 1519-1526.
5. Robinson DS, Hamid Q, Ying S, et al. Predominant Th2 like bronchoalveolar T lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 288-294.
6. Bendey AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils and cytokine mRNA expression for interleukin-4 and granulocyte macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthma. Am J Respir Cell Mol Biol 1993; 8: 35-42.
7. Hamid Q, Arzawt M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal biopsies from asthma. J Clin Invest 1991; 87: 1541-1546.
8. Linsley PS, Brady W, Gronaire L, Anello A, Damie NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and IL-2 mRNA accumulation. J Exp Med 1991; 173: 721-730.
9. Shahian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261: 609-612.
10. Linsley PS, Bruce W, Breslau L, Ledbetter JA, Mosmann TR, Coffman RL. Activation and CD28 expression on activated T cells. J Exp Med 1994; 179: 159-164.
Th2 cells and cytokines in allergic inflammation

protein antigens involves major histocompatibility complex (MHC) class I-restricted CD4+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993; 178: 899-899.

Ezard F, Wild MT, Guzman-Sanz JA, Le Gros G. Switch of CD8+ T cells to noncytolytic CD8+CD4+ cells that make TH2 cytokines and help B cells. Science 1993; 260: 1802-1805.

60. Seder RA, Paul WE, Davis MM, de St Groth BF. The presence of interleukin (IL-4) producing cells in vivo and in vitro. IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 1990; 172: 921-929.

61. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 12 exerts a differentially effect on airway hyperresponsive neonatal and adult human CD45R0+CD4+ T cells. J Clin Invest 1994; 94: 1352-1358.

62. Yoshimoto T, Paul WE, Klinman DM, Kinzer C, Shirai A, Paul WE, Kinzer C, Shirai A, Paul WE, Klinman DM. IgE receptor-positive non-B/non-T cells dominate the production of interleukin 4 and interleukin 6 in immunized mice. Proc Natl Acad Sci USA 1998; 95: 6880-6884.

63. Brinkmann V, Heusser C, Buer C, Klicshoff B, Ezard F. Interferon-α suppresses the capacity of T cells to help antibody production by human B cells. J Immunol Res 1992; 12: 267-271.

64. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vitro immunoglobulin E isotype selection. Ann Allergy Immunol 1990; 65: 303-305.

65. Brinkmann V, Geiger T, Allman S, Heusser CH. Interferon-α increases the frequency of interferon-gamma-producing human CD4+ T cells. J Exp Med 1993; 170: 1655-1665.

66. Yuki K, Itto G, Shirai A, Paul WE, Klinman DM. IgE receptor-positive non-B/non-T cells dominate the production of interleukin 4 and interleukin 6 in immunized mice. Proc Natl Acad Sci USA 1998; 95: 2524-2528.

67. Wong DTW, Elovic A, Matossian K, et al. Eosinophils express transforming growth factor alpha. J Exp Med 1990; 172: 673-681.

68. Wong DTW, Elovic A, Matossian K, et al. Eosinophils express transforming growth factor beta 1. Blood 1991; 78: 2707-2707.

69. Finkelman FD, Madden KB, Cheever AW, et al. Effects of IL-12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 1994; 179: 1563-1572.

70. Shu U, Demuzere CE, Iyden B, Podolski F, Stern AI, Delespesse G. Interleukin 12 exerts a differential effect on airway hyperresponsive neonatal and adult human CD45R0+CD4+ T cells. J Clin Invest 1994; 94: 1352-1358.

71. Sypol JP, Chang CL, Major SE, et al. Resolution of a conspicuous leukemic interferon-12 initiates a protective T helper type 1 immune response. J Exp Med 1995; 177: 1791-1803.

72. Finkelman FD, Madden KB, Cheever AW, et al. Effects of IL-12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 1994; 179: 1563-1572.